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Abstract 
Metabolic syndrome is often defined by the presence of several factors, including 
accumulation of abdominal fat, high blood pressure and high blood glucose levels, that increases 
the risk of developing heart disease, diabetes and cancer. The development of metabolic syndrome 
has been shown to be very closely linked to lack of physical activity and is increasing concurrent 
with the rise of obesity rates among adults. Development of metabolic syndrome can have 
detrimental physiological effects throughout the body and can lead to the development of Non-
Alcoholic Fatty Liver Disease (NAFLD). Proper liver function is crucial for the health of the body 
since it is the site of essential processes such as protein production, blood clotting, metabolism of 
cholesterol, glucose and iron. Metabolic syndrome contributing to NAFLD can lead to liver 
dysfunction, hepatitis, cirrhosis, and hepatocellular carcinoma. In this study we used liver RNA 
from our diet-induce obesity mouse model (mice fed with a 60% fat diet) to characterize the 
transcriptional landscape of NAFLD and compare it to the transcriptional signature of healthy 
control mice (mice fed with a 10% fat diet). Understanding the transcriptional differences between 
these two groups can aid in the understanding of NAFLD and consequent liver pathobiologies. 
More importantly, the transcriptional signatures identified could also help early detection of these 
diseases through the identification of novel markers. In this study, we observed significant down-
 regulation of genes associated with metabolic processes, and significant up-regulation of genes 
involved in immune responses. Additionally, we also identified up-regulated transcripts in our 
obese mice reported to be involved in hepatocellular carcinoma and fibrosis. However, the NAFLD 
livers did not demonstrate histological evidence of carcinoma and/or fibrosis. Therefore, the 
NAFLD livers already expressed a premalignant signature in the absence of any other indication 
of cancer.  In conclusion, the identification of genes downregulated in metabolic processes and up-
regulated in immune responses indicate that our model is indeed exhibiting liver disease. 
Moreover, the finding of a premalignant signature suggests that NAFLD may begin to progress 
towards hepatocellular carcinoma much earlier than previously thought.  
Introduction 
Metabolic Syndrome (MS) has been steadily increasing as a public concern throughout the 
years. MS includes a lot of risk associated with it, bringing an increased risk for type 2 diabetes,  
atherosclerotic cardiovascular disease, and chronic kidney disease(1,2). The increase of risk 
factors has been directly associate with glucose intolerance or insulin resistance, obesity, 
hypertension, proinflammatory state, and dyslipidemia (2-4). Many other diseases run parallel to 
the risk factors mentioned above, therefore, with the rise of obesity in the American population, 
the prevalence of metabolic syndrome will continue to rise, leading to the cause of other diseases. 
Worst prognosis such as Non-Alcoholic Fatty Liver Disease (NAFLD), cirrhosis, and ultimately 
hepatocellular carcinoma can then be direct results from the associated risk factors of metabolic 
syndrome(3). With the rise of obesity in the country, the risk for developing many diseases has 
been facilitated. Currently, NAFLD has become one of the most common liver diseases and has 
been estimated that 20% - 30% of individuals in the Western population is diagnosed with 
NAFLD(1, 5). With increasing amount of individuals being diagnosed with NAFLD, it has become 
 clear that this disease is not as benign as previously thought, and is now recognized as a major 
cause for liver-related morbidity and mortality(1). NAFLD is characterized with a wide 
histological spectrum, which includes simple steatosis and non-alcoholic steatohepatitis (NASH). 
Quantification of the hepatocytes containing fat droplets in the liver can give an indication into the 
severity of the steatosis, and the recommended lower threshold has been set to 5% of the liver mass 
being composed of hepatocytes containing fat(6). A histological result of above that threshold can 
result in a diagnosis of steatosis, which can potentially lead to the development of NAFLD. In 
addition, NAFLD has been directly associated with the same feature as metabolic syndrome, and 
has be thought to be the hepatic manifestation of this syndrome(1). Therefore, it has become a 
severe problem that needs more focused attention, and a facilitated way of being able to diagnose 
and perform proper interventions in patients.  
It has become clear that the risk factor between metabolic syndrome and NAFLD run 
parallel to one another, influencing each other to becoming worst prognosis. Obesity is one of 
these risk factors, and a contributor to many other diseases. Therefore, in our mice model, 
metabolic syndrome and ultimately NAFLD was induced via different diets, high fat diet (HFD) 
with 60% of their calories from fat, and low fat diet (LFD) with 10% of their calories from fat. 
Previous work from our group, showing the effects of obesity in our mice model allowed us to 
observe the many risk factors associated with metabolic syndrome. This previous study showed 
that mice after months in the different diets are able to develop insulin resistance, they become 
obese, and develop other health concerns that significantly reduce the quality of life and health of 
the mice(7). In addition to the already known factors, laboratory testing is used as the main 
diagnosis tool for determining NAFLD. On the extreme end, liver biopsies are also performed to 
observe for histological changes with the thresholds mentioned above(6). Although there is 
 diagnostics in place for NAFLD, there are many variables that can affect laboratory testing and its 
accuracy. Additionally, liver biopsies are also a very invasive method of performing diagnosis. 
For this reason, transcriptional regulation was of main focus in this study. We aimed to observed 
the overall regulation of different processes and pathways, and how they differ between the 
different samples under different diets.  
As mentioned before, our group has recently shown that these mice do in fact have the 
characteristics of metabolic syndrome, and recent histological work has characterized our obese 
mice with steatosis(7). This led us to the conclusion that our mice, aside from having developed 
metabolic syndrome, they were also diagnoses with NAFLD. Therefore, our study focused in 
observing the transcriptional differences between our obese mice in a high fat diet (HFD), and lean 
mice in low fat diet (LFD). We show that there are significant transcript differences between the 
two phenotypes, up-regulating inflammation-related processes and down-regulating metabolism-
related processes in HFD-fed mice compared to LFD-fed mice. Additionally, we also show that 
although our senescence-accelerated mouse prone (SAMP)6 mice do not show any histological 
characteristics of cancer/tumorigenesis or fibrosis, they are able to present a pre-malignant and 
pre-fibrotic signature consistent with early states of tumorigenesis and hepatocellular carcinoma.  
Materials and Methods: 
Mice Diet: 
 SAMP6 strain mouse were used in this study, with colonies established from eight females 
and four males purchased at 6 weeks of age (Harlan Laboratories, Indianapolis, IN) as has been 
done in previous study from our group(7). At 6–8 weeks of age, 25 mice each SAMP6 and AKR/J 
were fed the following diets: high fat diet (HFD) containing 60% calories from fat, 20% protein, 
and 20% carbohydrates (58Y1, Test Diet, Richmond, IN); low fat diet (LFD) containing 10.2% 
 calories from fat, 18.3% protein, and 71.5% carbohydrates (58Y2, Test Diet, Richmond, IN), or 
regular diet (RD) grain-based mouse chow containing 13.50% calories from fat, 28.50% protein, 
and 58% carbohydrates (#5001, Lab Diet, St. Louis, MO). The mice were fed daily with fresh 
high, low fat or regular chow (5 g/day) for 6 months(7). 
Liver Tissue Harvest: 
 Mice were sacrificed and the tissue snap frozen in liquid nitrogen. Tissue was immersed in 
liquid nitrogen and kept there for the remaining of the procedure. Upon the completion of the 
harvest procedure, the tissues are stored in sterile falcon tubes and later in dry ice. Tissues are then 
frozen at -70 oC until the homogenization procedure was performed. 
Homogenization Procedure: 
 Homogenization of the tissue was done using an electric homogenizer. A transfer of at least 
1mL TRIZOL reagent (Invitrogen, Carlsbad, CA) per 100mg of tissue to be homogenized was 
done into a falcon tube and homogenized the tissue until the tissue was completely dissolved in 
solution.  
RNA extraction: 
 Mixture was vortexed thoroughly.  Once homogenized, aliquots of the solution were 
transferred to Eppendorf tubes and left in TRIZOL at room temp for five minutes. Phase Separation 
was then performed using 200 µl chloroform per 1mL TRIZOL (originally used), vortexed for 15 
seconds, and left at room temp for 5 minutes. Samples were then centrifuged at 12,000g for 15 
minutes at 2-8 oC. RNA Precipitation was done following centrifugation, there were three phases 
visible within the tube. The aqueous phase (top) was transferred to a fresh RNAse free tube, being 
careful not to contaminate the solution with the other phases. Added 500 µl isopropanol per 1mL 
TRIZOL (originally used) to the new tube and incubated at room temp for 10 minutes. Samples 
 were then centrifuged at 12,000g for 10 minutes at 2-8 oC. RNA wash and resuspension was done 
following centrifugation, and the supernatant removed. RNA pellet was washed with 70% cold 
ethanol in DEPC water / 1ml TRIZOL (originally used) and vortexed. Samples were then 
centrifuged at 7,500g for 5 minutes at 2-8 oC. Supernatant was removed. Remaining of ethanol 
was allowed to air dry for 5 minutes. Pellet was then resolved in 50 µL of DEPC water. 
Library Preparation: 
 Library preparation of the two treated, HFD (n = 3) and LFD (n = 3), SAMP6 mice were 
done in biological triplicates. Samples were prepared by the Genomics Core in the Center for 
Personalized Cancer Therapy at UMass Boston. Total RNA samples were DNAse treated and 
300ng was used as input to create single indexed (6 base pairs) RNA-Seq libraries using the TruSeq 
RNA preparation kit according to the manufacturer’s protocol(8). Samples were pooled together 
and sequenced on a two-lane flow cell using on-board cluster generation with the Illumina 
HiSeqTM 2500 instrument. 
HiSeqTM 2500: 
 RNA-Seq libraries were sequenced on the HiSeqTM 2500 loaded with software version 3. 
A 51 cycle paired-end rapid run of the single indexed RNA-Seq libraries was performed. Raw data 
of the Bcl base call files were then demultiplexed upon completion.  
NanoString: 
 NanoString nCounterTM Mouse Inflammation v2 panel consisting of 248 inflammation-
related mouse genes and 6 internal reference genes was performed in the same total RNA isolated 
from the liver tissues. Using 100ng input of total RNA was used in preparation for the 
hybridization reaction following NanoString’s nCounterTM Gene Expression Assay Manual(9). 
Post hybridization reaction, samples were then placed in the nCounter Prep Station v4.1.0.1 and 
 nCounter Digital Analyzer v3.1.0.1 for finalization of the protocol and data collection. Data was 
analyzed using the nSolver Analysis Software v2.5. 
Bioinformatics Analysis: 
• Samples 
3 high fat and 3 low fat mice were used for the the purposes of this experiment. 
Sample names from the sequencing were as follows: 
 High Fat mice: NK001_1_CGATGT, NK002_2_TGACCA, and 
NK003_3_ACAGTG 
 Low Fat mice: NK004_4_GCCAAT, NK005_5_CAGATC, and 
NK006_6_CCTGTA 
• Bcl basecall files to FASTQ Conversion 
Bcl basecall files were converted to FASTQ format using Illumina’s bcl2fastq 
conversion tool v1.8.4. Stringent conversion parameters were set by not allowing a 
mismatch in the index during the demultiplexing process. Additionally, FASTQ files were 
created overwriting the default parameter to split the files after 4 million reads, generating 
a single FASTQ file for each sample replicate.   
• Alignment to reference genome 
Alignment of reads were carried out using Tophat v2.0.14(10, 11) post FASTQ file 
conversion using Illumina’s bcl2fastq tool v1.8.4. Alignment parameters for Tophat 
consisted of utilizing the default parameters, which were sufficient for downstream 
analysis of data. The reference genome file used for the alignment was the mm10 Genome 
Reference Consortium GRCm38.p4(12, 13), and the gene transcript file provided by 
iGenomes (Illumina). 
 • Differential Expression Analysis 
Cufflinks v2.2.1 was used to estimate the relative abundance of transcripts aligned 
for all the samples(14). Cuffdiff v2.2.1 was used to perform the differential gene expression 
analysis post quantification of the transcripts for the samples(15). Analysis was performed 
against the low fat mice to elucidate up-regulated and down-regulated genes in high fat 
mice. The statistical cutoff was set to p-value ≤ 0.05. 
• Pathview 
Pathview v1.10.1 was used in order to perform gene set enrichment analysis to 
elucidate the top pathways cellular pathways that are overall up-regulated, or down-
regulated when compared to LFD(16). In addition, selected pathways of interest were also 
picked for visualization of the overall regulation of the pathways. The statistical cutoff was 
set to a q-value ≤ 0.05. 
• Network Analysis 
Network Analysis of the differential expression analysis was done using Cytoscape 
v3.3.0(17). Gene sets of 2-fold or higher genes up-regulated in HFD mice, and 0.1-0.5-fold 
lower down-regulated genes in the HFD mice with a p-value cutoff of 0.05 was used as the 
gene set entry for the network analysis of the mouse interactome. Interactome used for this 
analysis was provided by the Cytoscape program, loaded with the mouse interactome from 
BioGRID database release 3.4.129.  
• Gene Ontology 
Gene ontology analysis of the gene sets, both 2-fold or higher genes up-regulated 
in HFD mice, and 0.1-0.5-fold lower down-regulated genes in the HFD mice were 
performed using ClueGO and GOstats. ClueGO v2.2.3 was used for the analysis of the two 
 sets of genes, both up-regulated and down-regulate genes in the HFD mice(18). GOstats 
v2.36.0 was used to observe for overexpression of the biological processes of up-regulated 
and down-regulated genes in the HFD mice compared to LFD mice(19). Statistical cutoff 
for both computational programs was set to a p-value of ≤ 0.05. 
• nSolver Analysis 
Raw nCounter data was analyzed using the nSolver Analysis Software v2.5.34. 
Normalization of the data was carried out in two different steps. First using the geometric 
mean of the positive controls probes provided by nanoString, the data was normalized to 
this prior to normalization using the housekeeping probes. Normalized data, and genes with 
counts higher than 10 were then used for the rest of the analysis. All statistical significance 
was set to a p-value of ≤ 0.05. 
Results 
High Fat Induces Metabolic Syndrome Leading to NAFLD 
It has been widely shown in the literature that excess of white adipose tissue (WAT) can 
lead to several health concerns, including inflammation, metabolic syndrome, type 2 diabetes, and 
NAFLD(20). Excess WAT or fat was observed in our SAMP6 mice model as can be seen in the 
lateral abdominal area of the mice in Figure 1A. The mouse on the left, low fat diet (LFD) mice, 
shows a relatively normal liver size compared to the mice on the right, high fat diet (HFD), where 
the liver is significantly bigger in size. This can be a direct effect of the inflammation aspect that 
that the excess WAT is contributing to. In figure 1B, liver histology images of the mice liver, both 
HFD and LFD can be observed. Images of the liver histology for HFD-fed mice show various 
white spotting of fat in the liver. A normal liver’s mass consists of about 5-10% of fat, on the other 
hand a higher fat percentage is considered steatosis as it was identified by the histologist. Lastly, 
 previous work by our research group was able to identify that the SAMP6 strain mice, under the 
same dietary conditions, are able to various health concerns(7). These mice developed type II 
diabetes, as previously shown by our research group, a condition that has been tied to having 
increased risks of developing NAFLD. Taken all together, the SAMP6 mice model used in this 
study has been able show the diseases associated with metabolic syndrome, and being in different 
diets, develops to NAFLD. 
HiSeq Results Validation Through nanoString Analysis 
Two different techniques were used to look into the differential expression in genes. A total 
RNA HiSeq run was performed to observe the gene expression differences between the two 
different samples. In addition, a nanoString mRNA inflammation panel was also performed as a 
validation step for the HiSeq data. In figure 2A-B, we are able to observe a correlation between 
transcripts both up and down-regulated in our sample dataset. This was very encouraging to 
observe due to that nanoString mRNA panel was very specific to mRNA inflammation transcripts. 
Taken all together, the results obtained allowed for the downstream analysis using the HiSeq 
dataset, which has a wider variety of tools available for carrying out differential analysis. 
Therefore, data shown in sections below were all carried out using the HiSeq dataset.  
Transcriptome Regulation of Inflammatory and Metabolic Response 
Differential analysis of these two different conditions was assessed at the gene set level, in 
order to observe what processes or gene ontology the transcripts are regulating. Two different gene 
sets were taken for this step of the analysis, we observed the regulation of 2-fold up-regulated and 
0.1-0.5-fold down-regulated in HFD-fed mice. Gene ontology was carried out using two different 
techniques as outlined in the methods section above. Using GOstats, we were able to generate 
figures 3A and 3C, which shows counts of genes associated with specific biological processes in 
 the cell. In addition, ClueGO was used to look at gene ontology of biological processes in both 
gene sets as shown in figure 3B and 3D. In both figures 3A and 3B, the gene counts and gene 
ontology can be observed for the 2-fold or higher up-regulated genes in the HFD-fed mice 
compared to LFD-mice. We can observe a strong regulation of genes that are directly associated 
with response to stimulus and immune response. This up-regulation reflects the metabolic 
syndrome-induced inflammation in the HFD-fed mice. On the other hand, for gene set of 0.1 to 
0.5-fold down-regulated transcripts in HFD-fed mice, the results are shown in figure 3C and 3D. 
In this figures, we observed that metabolic processes are overall down-regulated in HFD-fed mice 
when compared to LFD-fed mice. This down-regulation observed reflects the fatty liver organ 
dysfunction that could have been a direct effect of the HFD that mice underwent during the six 
months. Taken all together, the up-regulation of immune-related transcripts and the down-
regulation of metabolism-related transcripts shows the stress caused by metabolic syndrome-
induced inflammation and this paired with the decrease of metabolism function has a significant 
effect in the health and quality of life of the mice. 
Top Regulated Pathways in NAFLD Mice 
Additionally, the complete HiSeq dataset of the differential expressed transcripts 
containing both up-regulated and down-regulated transcripts in HFD mice also underwent gene-
set enrichment analysis using the Pathview tool as outlined in the methods above. In figure 4, we 
have tables of overall up-regulated and down-regulated pathways in HFD-fed mice compared to 
LFD-fed mice. Figure 4A shows the top significant (p-value ≤ 0.05) overall up-regulated pathways 
given the transcripts used as input. It can be observed that the “Complement and Coagulation 
Cascades” came as the top significant up-regulated pathway, which is able to correlate with recent 
studies. Recent studies by Rensen S. S. et al. has shown the implications of complement transcripts 
 in NAFLD, which is able to support our findings(21). In addition, the Complement Cascade has 
also been shown to be up-regulated in response to inflammation, which reflects the metabolic 
syndrome-induced inflammation. In addition, many of the pathways also shown in figure 4A has 
been implicated in inflammation response, once again being able to support the data found during 
the gene ontology analysis and inflammation of the liver as it was observed in figure 1B.  
Gene set enrichment analysis was also performed to look at the overall down-regulated 
pathways using the Pathview tool. Figure 4B, shows the significantly (p-value ≤ 0.05) down-
regulated pathways in HFD-fed mice compared to LFD-fed mice. Once again, just like the gene 
ontology analysis, we observed a down-regulation of critical pathways implicated in metabolism 
processes. As previously mentioned, this could be a direct effect of the liver organ dysfunction at 
not being able to properly metabolize nutrients. Taken this data together, it is able to show the 
severe effect that HFD-fed mice with NAFLD have, which correlates with current understanding 
of NAFLD in the patients.  
Correlation between NAFLD, Hepatocellular Carcinoma Transcripts and pre-fibrotic 
signatures 
It is well understood that NAFLD can eventually lead to a worst prognosis like cirrhosis 
and hepatocellular carcinoma if not treated in time or left unattended(22). Currently different 
biomarkers have been associated with Hepatocellular Carcinoma, therefore, we aimed to observe 
if any of these known biomarkers can be found in our samples when comparing HFD-fed mice to 
LFD-fed mice(23). In figure 5, we are able to observe transcripts that have implications in 
hepatocellular carcinoma that were also found in our mice model. Performing differential 
expression analysis in the sample, our group was able to observe the up-regulation of transcripts 
relevant to hepatocellular carcinoma. Transcripts such as growth factors and heat shock proteins 
 observed in this figure can directly explain the stress and the over-grown liver observed in figure 
1A. The growth factors observed up-regulated in HFD-fed mice provide a pre-malignant signature 
implicated in cancer, with potential for uncontrollable cell growth, a characteristic unique to 
cancer(24). In addition, our group also observed a strong up-regulation of a pre-fibrotic pathway, 
the “ECM-Receptor Interaction”, as can be observed in figure 6. The ECM has the vital role that 
contains the information, maintenance, and sustainability necessary for normal function of 
different tissues(27). It is widely understood that up-regulation of extracellular matrix (ECM)  
proteins have been implicated in fibrosis, and can further the thickening and scarring of connective 
tissue(25, 26). In figure 6, collagen can be observed to be up-regulated, and recent studies have 
shown how collagen production and deposition contributes to the development of fibrosis(27, 28). 
Although our mice do not show fibrotic livers, an up-regulation for collagens can indicate the early 
phases of fibrosis. Taken this data together, it can be concluded that although our mice do not 
exhibit any cancerous phenotypes, they are able to present a pre-malignant and pre-fibrotic 
signatures consistent with early stages of tumorigenesis. 
Discussion 
Understanding the transcriptional response of diseases can shed light into learning more 
about different diseases.  In metabolic syndrome and NAFLD, there are many contributors to the 
disease, and having a global understanding of the transcriptional response can aid in the diagnosis 
of these diseases. Previous research from our group showed that these SAMP6 mice are able to 
develop type 2 diabetes as a consequence from being obese, one of the many conditions connected 
to metabolic syndrome, which reduced the quality of life and health of the mice(4, 7). Many studies 
have associated insulin resistance, obesity, hypertension, proinflammatory state, and dyslipidemia 
with metabolic syndrome(2-4). Many of these factors are able to directly affect other organs, and 
 for the purpose of this study, we aimed to focus on NAFLD and its effect in the transcriptional 
regulation of the liver. As stated before, inflammation plays a crucial role in NAFLD and the 
progression of the disease. Many of the genes up-regulated in HFD-fed mice were stimulus and 
immune-related when compared to LFD-fed mice. It was encouraging to be able to find in our 
datasets many immune-related responses in the HFD-fed mice, indicating that this response might 
be a direct result to the metabolic syndrome-induced inflammation of the liver as was previously 
indicated. Additionally, we also were able to observe the down-regulation of the metabolic 
processes-related genes, which was able to indicate the fatty liver organ dysfunction as previously 
noted. On the other hand, our group was also able to observe what pathways these genes were 
mainly regulating. In HFD-fed mice, the significant up-regulated “Complement and Coagulation 
Cascades” pathway was the top up-regulated pathway in our study. Previous studies have 
implicated the complement-related genes as a response from NAFLD, as described by S. S. Rensen 
et al.(21). This finding and the fatty liver histology of the HFD-fed mice containing steatosis 
allowed us to conclude that our mice were indeed suffering from NAFLD. The immune-response, 
repressed metabolic processes, and the up-regulation of the complement pathway allows us to 
observe this unique transcriptional response to NAFLD, which can aid in further understanding 
this disease. Lastly, the pre-malignant and pre-fibrotic up-regulation of transcripts in the HFD-fed 
mice allowed us to observe something very unique. Although our mice did not show any cancerous 
or fibrotic phenotype, there were able to show these transcripts, such as growth factors, heat shock 
proteins, and collagen which have been implicated in early stages of tumorigenesis and 
hepatocellular carcinoma(23, 27, 28). Taken this data together, our group was able to find a 
transcriptional response and signature unique to NAFLD and very early stages of tumorigenesis. 
This study was able to provide transcriptional information of the NAFLD disease, and increase 
 our understanding of the cellular response in mice model, which can be potentially translated to 
the same response in the human population.  
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Figures 
Figure Legends: 
Figure 1: A. Two mice showing the effect of diet in the liver, showing a normal liver (left) and a 
fatty liver (right). In addition, it can be observed the excess amount of white adipose 
tissue in the high fat diet mouse. B. Histological images of both livers from HFD and 
LFD mice. Steatosis is evident in the high fat diet liver compared to low fat die mice(7).  
Figure 2: Both the nanoString (dark grey) and HiSeq (light gray) RNA analysis techniques identify 
the same up-regulated (A) and down-regulated (B) inflammatory-related genes.  
Figure 3: A-B. Significant up-regulation of genes directly associated with immune response and 
response to stimulus. This up-regulation of immune response reflects the metabolic 
syndrome-induced inflammation. C-D. Significant down-regulation of genes directly 
associated with metabolic processes. This down-regulation of metabolic processes 
reflects fatty liver organ dysfunction. 
Figure 4: A. Top significant up-regulated pathways in HFD mice when compared to LFD mice. 
Up-regulated pathways have implications in inflammatory response and supports the data 
shown in Figure 3. B. Top significant down-regulated pathways in HFD mice when 
compared to LFD mice. Down-regulated pathways have implications in metabolic 
response and supports the data shown in Figure 3. 
Figure 5: NAFLD Livers Demonstrate a Premalignant Signature. Growth factors and heat shock 
proteins also found in hepatocellular carcinoma were found up-regulated in HFD mice 
compared to LFD mice. No tumors were identified in the NAFLD livers. Therefore, the 
 mouse fatty liver demonstrates a pre-malignant signature consistent with early stage of 
tumorigenesis. 
Figure 6: NAFLD Livers Demonstrate a Pre-Fibrotic Signature. We have observed that HFD-fed 
mice also show an up-regulation for collagen and extra cellular matrix related proteins 
that have been been implicated in fibrosis. Therefore, our mice model also shows the pre-
fibrotic signature that is consistent with early development of cirrhosis and hepatocellular 
carcinoma. 
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